Avirmax is developing adeno-associated virus (AAV)-mediated gene therapy drugs that target chronic eye diseases. Recombinant AAVs (rAAVs) are promising vectors for gene therapy as they transduce both dividing and quiescent cells, have low toxicity and inflammation in target tissues. Using their AAV capsid engineering technology, Avirmax is finding effective solutions for simple administration of rAAV vectors via an intravitreal route with high efficiency of transduction of retinal cells. In addition, Avirmax is using their proprietary transgene optimization technology to enhance gene expression for their lead therapeutic genes of interest. Avirmax’s technology has been used by several gene therapy companies to produce clinical material for clinical development.

Avirmax

Founded: 2019
Location: Hayward, CA
Employee range: 11 - 50
Clinical stage: Clin0
Therapy area: wet AMD
Drug types: OPH
Lead product: ABI-110
Funding: &lt;10M

Business:

Drug notes:

About:

Jobs:

News: